Q-omics provides the consensus-scored MIR182 profile across patient tissues and cancer cell-line models. MIR182 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MIR182 is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, MIR182 RNA expression shows 6,604 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, HNSC, and GBM as cancer lineages where MIR182 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR182 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR182 survival associations across molecular data types. MIR182 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR182 RNA expression–survival associations across cancer types. High MIR182 expression shows unfavorable associations in UCEC, COAD, KICH, PAAD, LUAD and ACC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MIR182 RNA expression.
This table summarizes MIR182 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR182. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR182 shows higher tumor expression in HNSC. The HNSC box plot shows higher MIR182 RNA expression in tumor versus normal tissue (log2 FC = +0.092, t-test p = .043).
This table shows molecular features associated with MIR182 in patient tissues and cancer cell lines. In patient samples, MIR182 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
